Resources

This document provides general feedback on the Grant Opportunity for Heart Disease and Stroke – Support for Recovery GO2797 for the information of grant applicants.

This document provides general feedback on the grant opportunity for Macular Disease – Consumer awareness and education – Population groups at risk for the information of grant applicants.

This report summarises developments in the national bowel and cervical screening programs and the National Cancer Screening Register since the initial privacy impact assessment was done.

Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 9th meeting on 17 June 2021.

The action plan aim to improve the quality of life for people living with chronic pain in Australia. 

This communique is for the meetings of the Advisory Committee on Health Emergency Response to Coronavirus (COVID-19) for People with Disability on 12 May 2021.

This fact sheet provides information for participants of the Australian Thalidomide Survivors Support Program about the categories of goods and services which are eligible to be claimed under the Extraordinary Assistance Fund (EAF).

This form is a template for health practitioners to provide evidence to support an eligible thalidomide survivor (patient) to receive support from the Extraordinary Assistance Fund (EAF) or the Health Care Assistance Fund (HCAF).

This fact sheet provides information about how participants of the Australian Thalidomide Survivors Support Program can make a claim to the Extraordinary Assistance Fund (EAF). The EAF helps cover the costs of goods and services to assist with activities of daily living.

This fact sheet provides information about how participants of the Australian Thalidomide Survivors Support Program can make a claim to the Health Care Assistance Fund (HCAF). The HCAF helps cover out-of-pocket health care expenses incurred as a direct result of thalidomide injuries.

This fact sheet provides information for participants of the Australian Thalidomide Survivors Support Program about the categories of goods and services which are eligible to be claimed under the Health Care Assistance Fund (HCAF).

Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 8th meeting on 19 February 2021.

This fact sheet answers key questions about the review of Continuous Glucose Monitoring (CGM) products provided through the National Diabetes Services Scheme (NDSS).

Suppliers must use this form to make a submission to the Review of CGM products provided through the National Diabetes Services Scheme (NDSS).

Stakeholder organisations and other interested parties must use this cover sheet to make a submission to the Review of CGM products provided through the National Diabetes Services Scheme (NDSS).

Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 7th meeting on 22 and 23 October 2020.

Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 6th meeting on 25 and 26 June 2020.

Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 5th meeting on 16 and 17 April 2020.

This document states the outcome of BioMarin's application to include cerliponase alfa on the Life Saving Drugs Program.

This document states the outcome of Alexion Pharmaceuticals Australasia's application to include asfotase alfa on the Life Saving Drugs Program.